Targeting high circulating dipeptidyl peptidase 3 in circulatory failure

IF 9.3 1区医学 Q1 CRITICAL CARE MEDICINE

Critical Care Pub Date : 2025-07-31 DOI:10.1186/s13054-025-05545-x

Adrien Picod, Feriel Azibani, Veli-Pekka Harjola, Mahir Karakas, Antoine Kimmoun, Bruno Levy, Peter Pickkers, Holger Thiele, Uwe Zeymer, Karine Santos, Alexandre Mebazaa

引用次数: 0

Abstract

Circulating dipeptidyl peptidase 3 is a new biomarker linked to circulatory failure prognosis and pathophysiology and is a potential actionable therapeutic target. In this short review intended for the clinician, a question-and-answer format provides key insights on the nature of this biomarker and the therapeutical potential of its targeted inhibition in critically ill patients.

查看原文本刊更多论文

在循环衰竭中靶向高循环二肽基肽酶3

循环二肽基肽酶3是一种新的与循环衰竭预后和病理生理相关的生物标志物，是一种潜在的可操作的治疗靶点。在这篇针对临床医生的简短综述中，问答形式提供了关于这种生物标志物的性质及其在危重患者中靶向抑制的治疗潜力的关键见解。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Critical Care 医学-危重病医学

CiteScore

20.60

自引率

3.30%

发文量

348

审稿时长

1.5 months

期刊介绍： Critical Care is an esteemed international medical journal that undergoes a rigorous peer-review process to maintain its high quality standards. Its primary objective is to enhance the healthcare services offered to critically ill patients. To achieve this, the journal focuses on gathering, exchanging, disseminating, and endorsing evidence-based information that is highly relevant to intensivists. By doing so, Critical Care seeks to provide a thorough and inclusive examination of the intensive care field.